HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA)
Clinical trials for HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA) explained in plain language.
Never miss a new study
Get alerted when new HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA) trials appear
Sign up with your email to follow new studies for HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental injection targets tough blood cancers and anemia
Disease control Recruiting nowThis early-stage study tests a new treatment called GT801 in 28 adults with certain blood cancers (like leukemia and lymphoma) or an autoimmune blood disorder (AIHA) that have not responded to standard therapies. The treatment uses specially modified cells to target a protein cal…
Matched conditions: HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA)
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated May 17, 2026 07:05 UTC
-
New 'Off-the-Shelf' cell therapy targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests an experimental cell therapy called GT719 for adults with relapsed or refractory B-cell blood cancers (lymphoma and leukemia) that have not responded to standard treatments. The therapy uses donor-derived immune cells designed to attack cancer cells c…
Matched conditions: HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA)
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New cell therapy targets tough blood cancers in early trial
Disease control Recruiting nowThis study tests an experimental treatment called GT719 for adults with certain blood cancers (B-cell lymphoma or leukemia) that have not responded to standard therapy or have returned. The treatment is a type of cell therapy that targets a protein called CD19 on cancer cells. Th…
Matched conditions: HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA)
Phase: PHASE1, PHASE2 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated May 11, 2026 20:40 UTC